Background
==========

Although drug-eluting stents prevail in treating coronary heart disease (CHD), several concerns have already begun to rise publicly, including those regarding medical complications social burdens \[[@B1]\]. More cost-effective preventive treatments are called for; therefore, various studies have been conducted to identify the risk factors for CHD, which are classified into classical versus novel categories \[[@B2]\]. The former consists of aging, female sex, genetic factors, obesity, smoking, dyslipidemia, hypertension and diabetes mellitus while the latter includes several inflammatory markers such as hsCRP, IL-6, TNF-α, PAI-1, MCP-1 and adhesion factors such as ICAM-1 and VCAM-1 \[[@B2]\]. Some studies also divert their targets on the specific group of patients such as patients with hypertension, diabetes, metabolic syndrome or even SLE to personalize the existing grading systems of risk factors including the classic Framingham, Reynolds, SCORE and ASSIGN \[[@B2]\]. Insulin resistance, frequently appears in various clinical settings such as hypertension, diabetes and metabolic syndrome and is believed to be responsible for connecting endocrinological disorders with their potential adverse cardiovascular complications based on its reciprocal relationship with endothelial dysfunction indicated by cellular, physiological, clinical, and epidemiological studies \[[@B3]-[@B5]\]. However, few studies have actually examined its relationship with the progression of coronary atherosclerotic plaques. The aim of our study was to explore the effect of insulin resistance on the progression atherosclerotic plaques in patients with CHD.

Methods
=======

Since June 7^th^, 2007 to Dec 30^th^, 2011, subjects were identified and screened from patients seeking a planned percutaneous intervention for suspected new onset of CHD based on the clinical presentation, which was categorized as ECG abnormality (only positive stress ECG), stable angina (stable exertional symptoms only), unstable angina (progressive symptoms or symptoms at rest), or MI (creatinine kinase \[CK\] level \>636 IU/L and creatinine kinase-myocardial band isoenzyme \[CK-MB\] index \>6%) in the catheter Lab at the Shanghai Ruijin Hospital which is affiliated with the Shanghai Jiaotong University School of Medicine . Written consent was obtained from all individuals before they were enrolled in the study. Their medical histories were obtained and recorded, and pertinent baseline laboratory studies were drawn before cardiac catheterization while BMI and GFR were calculated. All patients were treated with IV heparin and combined antiplatelet therapy, while the use of IIb/IIIa inhibitors was at the operator's discretion. Telephone interviews were performed at 6 months and participants were readmitted for routine angiographic follow-up 1 year after the procedure, including those with normal angiography at their index visits. Necessary cardiac catheterization was performed for recurrent symptoms or objective evidence of ischemia. Individuals were excluded from the study if they fell into one of the following criteria: Patients with histories of CHD or prior coronary revascularization; patients undergoing CABG instead of stenting; patients with heart failure or any kind of cardiomyopathy; patients with familial hypercholesterolemia; patients with severely impaired liver or renal function; patients with a terminal illness with a life expectancy of less than 1 year.

Laboratory studies and the assessment of insulin resistance
-----------------------------------------------------------

After fasting for 12 hours, blood samples were drawn from the patients at 8 AM, including both fasting glucose and insulin concentration, HbA1c, hsCRP, liver function tests, lipid panel, BUN, creatinine and urine acid. In addition, OGTT and insulin concentrations were also obtained 2 hours after oral ingestion of 75 mg glucose by the central lab in the hospital without the knowledge of the study. Body mass index (BMI) was calculated as weight divided by height squared (kg/m^2^). We estimated insulin resistance by using the homeostasis model assessment index of IR (HOMA-IR) developed by Mathew \[[@B6]\], which was believed to have a close correlation with euglycemic clamp for use in cross-sectional studies \[[@B7]\]. We used the following formula HOMA-IR = baseline insulin concentration (U/mL) × baseline glucose concentration (mmol/L)/ 22.5 \[[@B6]\]. We obtained HOMA-IR values from 284 individuals and subsequently defined the cutoff value for insulin resistance as the upper quartile of HOMA-IR obtained from all the subjects involved in the study \[[@B8]\], which equals 3.458 in our study. Also glomerular filtration rate (GFR) was calculated by adopting the Cockcroft-Gault equation (for men: (140 − age × weight)/(72 × serum creatinine); for women: (140 − age × weight) / (72 × serum creatinine × 0.85)) \[[@B9]\].

Coronary angiography and Gensini score
--------------------------------------

Standard method was adopted and Judkins method was deployed. All patients were admitted to the hospital the day before CAG. The purpose of CAG was to diagnose any ischemic conditions such as angina. After administration of isosorbide dinitrate (2.5--5 mg bolus dose), the coronary arteries were evaluated by 2 experienced cardiologists. Narrowing of ≥50% in one of the three major coronary arteries or their major branches was judged significant while narrowing of \<5% was considered insignificant. We defined both residual narrowing of less than 20% and third class TIMI blood flow as successful outcomes of the procedure. The decision to deploy a balloon or use a specific drug-eluting stent was made by the cardiologists themselves. All angiograms were evaluated in similar angiographic angles, and the percentage of stenosis was determined with the use of calipers comparing the stenotic segment with the proximal, angiographically normal segment. Clodigrel, 75 mg per day, or ticlopidine, 250 mg twice per day, was administered for at least 12 months after the procedure and all patients received 100 mg aspirin per day. The same guidelines were implemented at 1-year follow-up for each subject. We also adopted the modified Gensini scoring system to evaluate both the baseline and the follow-up angiograms \[[@B10]\]. To summarize this scoring system, five points were given for left main lesion; 2.5 points for the proximal left anterior descending artery (LAD) or left circumflex (LCX); 1.5 points for mid-segment LAD; one point for the distal segment of LAD, first diagonal branch, LCX obtuse marginal branch or right coronary artery, and 0.5 points for the second diagonal branch or LCX posterolateral branch (Figure [1](#F1){ref-type="fig"}). To define the atherosclerotic plaque progression, we divided the following patients into the progression group: (1) patients who progressed from normal or insignificant angiogram to CAD; (2) Patients whose documented baseline lesions exacerbated in the same vessel; (3) Patients who progressed from their baseline CAD to new lesion(s) in a different vessel in one-year period. In addition, we classified those who had normal angiograms or similar CAD lesions at the first and following visits into the non-progression group \[[@B11]\].

![**Illustration of initial and follow-up visit angiograms obtained from one single participant.** Figure [1](#F1){ref-type="fig"}a depicts the index angiogram while Figure [1](#F1){ref-type="fig"}b is the follow-up angiogram from the same angle. To visualize the coronary lesions progression, two sets of colored arrows were presented to manifest different lesions. In addition, both lesions progressed during the 1 year follow-up. Figures were obtained with permission from the catheter lab at the Shanghai Ruijin Hospital, affiliated to Shanghai Jiaotong University School of Medicine.](1475-2840-11-71-1){#F1}

Definitions concerning conventional risk factors of CHD
-------------------------------------------------------

Patients who had smoked in the past year were considered current smokers. The definition of hypertension was a blood pressure that was equal to or higher than 140/90 mmHg after three measurements during the first visit or those with previously established diagnosis of hypertension or who were receiving antihypertensive drugs. Individuals with at least two fasting plasma glucose levels higher than 125 mg/dL or those being treated for diabetes with oral hypoglycemic agents and/or insulin were considered diabetic. Patients were considered dyslipidemic if the individual had cholesterol levels higher than 200 mg/dL or triglyceride levels higher than 150 mg/dL or if they were receiving lipid-lowering drugs.

Statistical analysis
--------------------

We adopted SPSS11.0 for all the statistical analyses related to the study. Measurement data were expressed as mean and SD while count data were presented as percentage (%). We used the paired t-tests for continuous variables and the χ^2^ test or the Fisher exact for categorical variables. Nonparametric methods were preferred to handle non-normally distributed data. Several conventional and novel risk factors such as age, body mass index (BMI), hypertension, DM, LDL-C, HbA1c, hs-CRP, urine MA/Cr and HOMA-IR were included in the multivariate logistic regression model to determine their independent effects on the progression of atherosclerotic plaques. Differences were considered statistically significant when the *p* value was less than 0.05.

Results
=======

Baseline demographics and lab results in the progression group versus non-progression group
-------------------------------------------------------------------------------------------

A total of 377 patients were consecutively included during the 4-year period and 366 participants received their follow-up angiography, with 198 individuals included in the progression group (including119 patients with new lesions in different vessels and 134 patients with progression in the same vessel) and 168 in the non-progression group. Table [1](#T1){ref-type="table"} lists baseline demographic data for both groups. No significant difference can be seen between the two groups except for DM prevalence (42.9% versus 30.4%, *p* = 0.013), NGR prevalence (33.8% versus 51.2%, *p* = 0.001) and oral glucose lowering agent (35.9% versus 21.6%, *p* = 0.002). In addition, both initial clinical presentations and medications patients received at discharge were similar in the two groups.

###### 

Baseline demographic data of the progression and the non-progression groups

  ---------------------------------------------------------------------------------------------------------
  **Variables**               **Progression Group**\   **Non-progression Group (n = 168)**   ***p*value**
                              **(n = 198)**                                                  
  --------------------------- ------------------------ ------------------------------------- --------------
  Age                         65.83 ± 11.46            64.74 ± 10.19                         0.375

  Sex(Man/Women)              158/40                   139/29                                0.474

  BMI (kg/m^2^)               25.47 ± 3.18             24.80 ± 3.63                          0.421

  Hypertension (%)            153 (77.3)               121 (72.5)                            0.289

  Diabetes (%)                85 (42.9)                51 (30.4)                             0.013

  NGR (%)                     67 (33.8)                86 (51.2)                             0.001

  IFG (%)                     13 (6.6)                 7 (4.2)                               0.362

  IGT (%)                     20 (10.1)                18 (10.8)                             0.865

  IFG + IGT (%)               13 (6.6)                 6 (3.6)                               0.241

  Initial admission n (%)                                                                     

  ECG abnormalities           24 (12.1)                12 (7.1)                              0.111

  Stable Angina               29 (14.6)                33 (19.6)                             0.204

  Unstable Angina             86 (43.4)                70 (41.7)                             0.733

  Non-ST elevated AMI         10(5.1)                  9(5.4)                                0.895

  ST elevated AMI             49 (24.7)                44 (26.2)                             0.752

  Medication (%)                                                                              

  Statin                      196 (99.5)               165 (98.8)                            0.468

  CCB                         67(29.6)                 55(32.9)                              0.806

  ACEI/ARB                    104 (53.6)               76 (46.1)                             0.154

  β-blocker                   164 (82.8)               128(76.6)                             0.141

  Oral glucose lowering dug   70(35.9)                 35(21.2)                              0.002

  Application of insulin      9(4.5)                   11(6.5)                               0.491
  ---------------------------------------------------------------------------------------------------------

Table [2](#T2){ref-type="table"} compares the lab results between the two groups, revealing that the progression group had a worse performance than the non-progression group in the glucose panel including fasting glucose (6.15 ± 1.81 versus 5.49 ± 1.25, *p* \<0.001 and 7.84 ± 1.80 versus 5.30 ± 1.22, *p* \< 0.005), OGTT (10.09 ± 4.17 versus 8.65 ± 3.41, *p* \< 0.001 and 9.68 ± 3.79 versus 8.47 ± 3.38, *p* = 0.002) and HbA1c (6.73 ± 1.40 versus 6.24 ± 0.98, *p* = 0.001 and 6.79 ± 1.53 versus 6.07 ± 0.78, *p* \< 0.001). Moreover, although significant differences in fasting insulin could be observed, the result for each subject was reversed between initial visit and 1-year follow-up (13.50 ± 26.58 versus 12.57 ± 27.04, *p* = 0.010 and 14.43 ± 19.01 versus 17.10 ± 60.81, *p* = 0.002). The Bonnet index, the log-transform of HOMA-IR, was markedly elevated in the progression group compared with non-progression group (1.79 ± 0.65 versus 0.41 ± 0.56, *p* \< 0.001 and 0.95 ± 0.84 versus 0.67 ± 0.95, *p* \< 0.001). The lipid panel between two groups was similar while both the urine mAlb/Cr at index visit (12.12 ± 49.70 versus 3.65 ± 18.74, *p* = 0.011) and GFR (73.52 ± 25.48 versus 71.55 ± 23.33, *p* = 0.049) at the follow-up visit were significantly higher in the progression group. Table [3](#T3){ref-type="table"} shows index clinical presentations and angiography characteristics. No significant difference could be observed between the two groups.

###### 

Comparison of laboratory results between the progression group and the non-progression group at first /follow-up visits

  ---------------------------------------------------------------------------------------------------------------------
  **Variable**\                  **Progression Group (n = 198)**   **Non-progression Group (n = 168)**   ***p*value**
  **Initial/ follow-up visit**                                                                           
  ------------------------------ --------------------------------- ------------------------------------- --------------
  Fasting glucose (mmol/L)       6.15 ± 1.81                       5.49 ± 1.25                           \<0.001

  7.84 ± 1.80                    5.30 ± 1.22                       0.005                                 

  OGTT (mmol/L)                  10.09 ± 4.17                      8.65 ± 3.41                           \<0.001

  9.68 ± 3.79                    8.47 ± 3.38                       0.002                                 

  Fasting insulin (mU/L)         13.50 ± 26.58                     12.57 ± 27.04                         0.010

  14.43 ± 19.01                  17.10 ± 60.81                     0.002                                 

  Postprandial insulin (mU/L)    78.31 ± 117.74                    62.43 ± 65.86                         0.388

  80.27 ± 71.31                  88.35 ± 107.35                    0.868                                 

  Bennett index                  1.79 ± 0.65                       0.41 ± 0.56                           \<0.001

                                 0.95 ± 0.84                       0.67 ± 0.95                           \<0.001

  HbA1c (%)                      6.73 ± 1.40                       6.24 ± 0.98                           0.001

  6.79 ± 1.53                    6.07 ± 0.78                       \<0.001                               

  hsCRP (mg/L)                   9.28 ± 13.56                      13.34 ± 22.51                         0.600

  6.55 ± 12.01                   2.68 ± 4.14                       0.048                                 

  BUN (mmol/L)                   5.44 ± 1.59                       5.45 ± 1.50                           0.941

  6.06 ± 1.90                    5.70 ± 1.48                       0.623                                 

  Creatinine (umol/L)            84.47 ± 18.34                     89.90 ± 36.51                         0.671

  93.11 ± 23.46                  87.28 ± 18.87                     0.585                                 

  Urine acid (umol/L)            339.83 ± 76.41                    339.30 ± 85.77                        0.878

  358.38 ± 81.25                 362.80 ± 79.00                    0.966                                 

  Urine Ma/Cr                    12.12 ± 49.70                     3.65 ± 18.74                          0.011

  16.00 ± 69.94                  2.09 ± 3.14                       0.366                                 

  GFR (ml/min)                   80.16 ± 25.46                     76.62 ± 28.98                         0.345

  73.52 ± 25.48                  71.55 ± 23.33                     0.049                                 

  Serum triglyceride (mmol/L)    2.13 ± 1.72                       1.86 ± 2.01                           0.072

  1.76 ± 1.34                    1.65 ± 1.50                       0.207                                 

  Serum cholesterol (mmol/L)     4.58 ± 1.22                       4.18 ± 1.09                           0.103

  2.08 ± 0.76                    2.05 ± 0.78                       0.412                                 

  HDL (mmol/L)                   1.05 ± 0.23                       1.05 ± 0.26                           0.706

  1.06 ± 0.26                    1.14 ± 0.26                       0.246                                 

  LDL (mmol/L)                   2.81 ± 0.96                       2.45 ± 0.84                           0.118

  2.08 ± 0.76                    2.05 ± 0.78                       0.412                                 

  Lpa (mmol/L)                   0.21 ± 0.21                       0.20 ± 0.18                           0.941

  0.21 ± 0.17                    0.30 ± 0.49                       0.317                                 

  ApoA (mmol/L)                  1.13 ± 0.22                       1.12 ± 0.20                           0.764

  1.11 ± 0.22                    1.12 ± 0.29                       0.738                                 

  ApoB (mmol/L)                  0.93 ± 0.28                       0.87 ± 0.26                           0.342

  0.80 ± 0.25                    0.77 ± 0.23                       0.225                                 

  Ejection Fraction              62.50 ± 9.06                      64.01 ± 6.86                          0.331

                                 62.62 ± 8.38                      62.62 ± 8.20                          0.153
  ---------------------------------------------------------------------------------------------------------------------

###### 

Index angiographic findings in the progression and non-progression groups

  --------------------------------------------------------------------------------------------------------------
  **Variables**                    **Progression Group**\   **Non-progression Group (N = 168)**   ***p*value**
                                   **(N = 198)**                                                  
  -------------------------------- ------------------------ ------------------------------------- --------------
  Baseline Clinical presentation                                                                  

  n (%)                                                                                            

  STEMI                            49 (24.7)                44 (26.2)                             0.752

  NSTEMI                           10 (5.1)                 9 (5.4)                               0.895

  SAP                              29 (14.6)                33 (19.6)                             0.204

  UAP                              86 (43.4)                70 (41.7)                             0.733

  ECG abnormalities                24 (12.1)                12 (7.1)                              0.111

  Number of vessel affected n      0.332                                                          

  (%)                                                                                              

  Without lesions                  2 (1.0)                  4 (2.4)                                

  Single vessel                    50 (25.3)                56 (33.3)                              

  Double vessel                    69 (34.8)                55 (32.7)                              

  Three vessel                     74 (37.4)                51 (30.4)                              

  Multiple vessel                  3 (1.5)                  2 (1.2)                                

  Characteristics of lesion n                                                                     

  (%)                                                                                              

  Diffuse lesion                   51 (25.8)                53 (31.5)                             0.221

  Calcification                    14 (7.1)                 21 (12.5)                             0.078

  Bifurcation                      13 (6.6)                 16 (9.5)                              0.296

  Opening lesion                   14 (7.1)                 16 (9.5)                              0.394

  Occlusive lesion                 37 (18.7)                33 (19.6)                             0.817
  --------------------------------------------------------------------------------------------------------------

We also obtained the changes in lab results by calculating the difference value between index and follow-up visits. Table [4](#T4){ref-type="table"} depicts the changes in lab results and their relationship with progression of atherosclerosis. During the course of the study, the glucose panel was elevated in the progression group compared with the non-progression group, including OGTT, which was significantly higher in progression group.

###### 

Comparison of changes in lab results between the progression and non-progression groups

  --------------------------------------------------------------------------------------------------------
  **Difference value of Variables**    **Progression group**\   **Non-progression group**\  ***p*value**
                                           **(n = 198)**              **(n = 168)**         
  ----------------------------------- ------------------------ ---------------------------- --------------
  Glucose                                   0.21 ± 2.20                −0.19 ± 1.27         0.136

  OGTT                                      −0.42 ± 3.92               −0.67 ± 2.87         0.025

  Insulin                                   6.00 ± 23.46               2.42 ± 11.90         0.347

  Insulin2h                                20.75 ± 58.80              14.65 ± 49.81         0.200

  SBP                                      −6.80 ± 21.76               2.68 ± 19.54         0.327

  DBP                                      −5.65 ± 11.95              −1.58 ± 13.80         0.637

  PP                                       −1.15 ± 18.76               4.26 ± 15.99         0.925

  MAP                                      −6.03 ± 13.22              −0.16 ± 14.05         0.517

  HbA1c                                     0.17 ± 1.28                0.02 ± 0.97          0.339

  hsCRP                                    −4.61 ± 18.68              −11.19 ± 21.90        0.659

  BUN                                       0.22 ± 1.39                0.48 ± 1.85          0.525

  Creatinine                                3.33 ± 16.63               4.28 ± 10.42         0.948

  UA                                       20.25 ± 49.91              41.06 ± 70.41         0.311

  GFR                                      −3.17 ± 12.38              −5.90 ± 14.05         0.520

  Urine Malb/Cr                             0.89 ± 66.12               0.20 ± 1.83          0.491

  TG                                        −0.29 ± 0.91               −0.36 ± 1.58         0.279

  TC                                        −0.90 ± 0.91               −0.57 ± 1.09         0.285

  LDL                                       0.16 ± 0.43                0.16 ± 0.30          0.321

  HDL                                       0.02 ± 0.22                0.06 ± 0.21          0.124

  Lpa                                       −0.01 ± 0.09               0.14 ± 0.59          0.114

  ApoA                                      0.02 ± 0.23                0.11 ± 0.25          0.919

  ApoB                                      −0.09 ± 0.26               −0.08 ± 0.23         0.609

  LVEF                                      −1.05 ± 5.65               −0.43 ± 5.83         0.561
  --------------------------------------------------------------------------------------------------------

We calculate the changes in laboratory results by deducting the index value from the follow-up value.

Follow-up lab results, angiogram and Gensini score between the Higher Insulin Resistant group and Lower Insulin Resistant group
-------------------------------------------------------------------------------------------------------------------------------

To investigate the IR further, we divided all participants into the higher IR group (71) and the lower IR group (213) based on the HOMA-IR cutoff value, which was 3.458 in our study. Table [5](#T5){ref-type="table"} presents the lab results from follow-up visits between two groups. Subjects in the higher IR group had markedly elevated laboratory values compared to the lower IR group, including BMI (27.69 ± 4.17 versus 24.13 ± 2.65, *p* \< 0.001), prevalence of hypertension (84.5% versus 70.0%, *p* = 0.013), prevalence of diabetes (62.0% versus 33.8%, *p* \< 0.001), fasting glucose (39.36 ± 9.93 versus 8.73 ± 3.43, *p* = 0.005), OGTT (10.51 ± 3.98 versus 8.73 ± 3.43, *p* = 0.002), fasting insulin (39.36 ± 96.93 versus 10.36 ± 9.56, *p* = 0.002), postprandial insulin (135.52 ± 148.57 versus 68.41 ± 60.23, *p* \< 0.001), bonnet index (0.95 ± 0.84 versus 0.67 ± 0.95, *p* \< 0.001) and HbA1c (6.79 ± 1.53 versus 6.07 ± 0.78, *p* \< 0.001 ). In addition, laboratory results such as GFR (79.46 ± 28.19 versus 70.38 ± 21.72, *p* = 0.016), serum triglyceride (2.09 ± 1.75 versus 1.52 ± 1.01, *p* = 0.002) and hsCRP (8.54 ± 13.78 versus 3.87 ± 7.45, *p* = 0.005) were significantly elevated in the higher IR group compared to the lower IR group. Characteristics of follow-up angiograms demonstrated that the higher IR group had a markedly increased rate of plaque progression (65.7% versus 47.6, *p* = 0.009), new lesion in different vessels (47.1% versus 27.4%, *p* = 0.002) and exacerbation of original lesion (22.9% versus 9.0%, *p* = 0.002) than in the lower IR group (Table [6](#T6){ref-type="table"}). Moreover, while the initial and follow-up Gensini scores were similar between these two groups (9.09 ± 14.33 versus 9.44 ± 12.88, *p* = 0.813 and 17.21 ± 18.46 versus 14.09 ± 14.18, *p* =0.358), the difference value during the follow-up is markedly elevated in the higher IR group than the lower IR group (8.13 ± 11.83 versus 4.65 ± 7.58, *p* = 0.019) (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}).

###### 

Comparison of lab results between the higher IR and lower IR groups (only variables considered statistically significant were listed)

  -------------------------------------------------------------------------------------------------
  **Variables**\               **Higher IR group**\   **Lower IR group (n = 213)**   ***p*value**
  **At the follow-up visit**   **(n = 71)**                                          
  ---------------------------- ---------------------- ------------------------------ --------------
  BMI                          27.69 ± 4.17           24.13 ± 2.65                   \<0.001

  Prevalence of hypertension   60 (84.5%)             148 (70.0%)                    0.013

  Prevalence of diabetes       44 (62.0%)             72 (33.8%)                     \<0.001

  Fasting glucose              7.84 ± 1.80            5.30 ± 1.22                    0.005

  OGTT                         10.51 ± 3.98           8.73 ± 3.43                    0.002

  Fasting insulin              39.36 ± 96.93          10.36 ± 9.56                   0.002

  Postrandial insulin          135.52 ± 148.57        68.41 ± 60.23                  \<0.001

  Bonnet index                 0.95 ± 0.84            0.67 ± 0.95                    \<0.001

  HbA1c                        6.79 ± 1.53            6.07 ± 0.78                    \<0.001

  GFR                          79.46 ± 28.19          70.38 ± 21.72                  0.016

  Triglycerides                2.09 ± 1.75            1.52 ± 1.01                    0.002

  hsCRP                        8.54 ± 13.78           3.87 ± 7.45                    0.005
  -------------------------------------------------------------------------------------------------

We divided the subjects into higher IR group and lower IR group based on the cutoff value, defined as the highest quartile of HOMA-IR from 366 participants and equaled to 3.458 in our study.

###### 

Comparison of the Gensini score and the pattern of follow-up angiograms between the higher IR and lower IR groups

  -----------------------------------------------------------------------------------------------
                             **Higher IR group**\   **Lower IR group (n = 213)**   ***p*value**
                             **(n = 71)**                                          
  -------------------------- ---------------------- ------------------------------ --------------
  Initial gensini score      9.09 ± 14.33           9.44 ± 12.88                   0.813

  Follow-up gensini score    17.21 ± 18.46          14.09 ± 14.18                  0.358

  Difference value during    8.13 ± 11.83           4.65 ± 7.58                    0.019

  1-year peroid                                                                     

  Follow-up angiogram (%)                                                           

  Progression of plaques     46(65.7)               101(47.6)                      0.009

  Revascularization          28 (40.6)              77(36.7)                       0.561

  New lesion in different    33 (47.1)              58 (27.4)                      0.002

  vessel                                                                            

  Exacerbation of original   16 (22.9)              19 (9.0)                       0.002

  lesion                                                                            

  In-stent restenosis        13(18.3)               31(14.6)                       0.449
  -----------------------------------------------------------------------------------------------

![**Comparison of Gensini scores between the higher IR group and lower IR group at the initial/follow-up visits.*p*\<0.05 was considered statistically significant.** Different colors represent different variables as listed on the right. Both index and follow-up Gensini score remained similar between the higher and lower IR groups (9.09 ± 14.33 versus 9.44 ± 12.88, *p* = 0.813 and 17.21 ± 18.46 versus 14.09 ± 14.18, *p* =0.358) while the difference value was significantly elevated in the higher than the lower IR group.](1475-2840-11-71-2){#F2}

![**Error bars demonstrating differences in index and follow-up Gensini score between the Higher and Lower IR group.** Each error bar represents a variable as listed on the X axis. The Y axis demonstrates the 95% confidence interval of each different Gensini score, including its mean value and standard deviation. The red circle indicates that difference value of Gensini score was statistically significant (8.13 ± 11.83 versus 4.65 ± 7.58, *p* = 0.019).](1475-2840-11-71-3){#F3}

Multivariable regression analysis of related risk factors towards atherosclerotic progression
---------------------------------------------------------------------------------------------

We assessed the impact of conventional and novel risk factors on the coronary atherosclerosis progression by using a multivariate logistic regression analysis (Table [7](#T7){ref-type="table"}). Risk factors including age, sex, BMI, prevalence of hypertension or diabetes, HOMA-IR \> 3.458, HbA1c, hsCRP, LDL-C, urine MA/Cr and change in OGTT were entered in the model and the results revealed that both HOMA-IR \> 3.458(OR = 4.969, *p* = 0.010) and HbA1c (OR = 1.721, *p* = 0.034) were independent predictors of progression of coronary lesions.

###### 

Regression analysis of risk factors for plaque progression concerning all participants

  **Variable**        **OR value**   **95%CI**     ***p*value**
  ------------------- -------------- ------------- --------------
  HOMA-IRI \> 3.458   4.969          0.630-6.475   0.011
  HbA1c               1.721          0.256-4.515   0.034

Abbreviations: CI, confidence interval; HbA1c, glycosylated hemoglobin; HOMA-IRI, homeostasis model assessment insulin resistance index; hsCRP, high sensitive C - reactive protein; OR, odds ratio.

Binomial regression analysis was performed across the entire study group. Regression model included both conventional and novel risk factors for coronary plaque progression such as age, sex, body mass index, hypertension, diabetes mellitus, follow-up urine microalbumin/creatinine, follow-up hsCRP, follow-up HbA1c, follow-up LDL. Change in OGTT was also included.

We then divided all subjects into the diabetic (n = 136) and non-diabetic groups (n = 230) to investigate the role of insulin resistance in the development of atherosclerotic plaques separately. The same binomial regression models were set up except the input of prevalence of diabetes mellitus (Table [8](#T8){ref-type="table"}). Insulin resistance remained an independent predictor for progression of coronary lesions in both groups according to the result. In addition, because HOMA-IR could be modeled as a linear continuous variable or a categorical variable divided by its cutoff value \[[@B12],[@B13]\], we subsequently tested HOMA-IR from both perspectives. The result revealed that HOMA-IR was an independent predictor of atherosclerotic progression, which was consistent with our early findings.

###### 

Logistic Regression of Risk Factors in both Diabetic Participants and non-Diabetic Participants

  **Subgroups**   **Variable**        **OR value**   **95%CI**     ***p*value**
  --------------- ------------------- -------------- ------------- --------------
  Non-DM          HOMA-IRI \> 3.458   7.528          0.973-4.300   0.034
  DM              HOMA-IRI \> 3.458   7.590          0.987-4.220   0.040

Abbreviations: CI, confidence interval; DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; HOMA-IRI, homeostasis model assessment insulin resistance index; hsCRP, high sensitive c-reactive protein; OR, odds ratio.

Binomial regression was performed separately in the non-DM (n = 230) and DM groups (n = 136). The model included both conventional and novel risk factors for coronary plaque progression such as age, sex, body mass index, hypertension, follow-up urine microalbumin/creatinine, follow-up hsCRP, follow-up HbA1c, follow-up LDL.

Discussion
==========

Our study explored the effect of insulin resistance on the progression of atherosclerotic plaques over a 1-year follow-up interval. The difference value of Gensini score between the higher IR group and the lower IR group was statistically significant and the binomial multivariate regression models contended that insulin resistance was an independent predictor of atherosclerotic progression in patients with coronary heart disease irrespective of the individual's diabetes status. Insulin resistance generally occurs in cluster with other risk factors including hyperglycemia, dyslipidemia and inflammatory conditions. IR itself is a phenomenon that decreases the effects produced by the normal activity of insulin \[[@B13]\]. In addition, one of its key biochemical defects lies in the specific impairment of PI3K-dependent signaling pathways while other pathways including MAPK were intact \[[@B14]\], which results in the overproduction of ET-1 over eNOS, leading to endothelium dysfunction and enhanced levels of VCAM-1 and MCP-1, eventually contributing to the formation of atherosclerotic plaques \[[@B15]\]. Early studies have already supported the idea that IR is an important predictor of CHD \[[@B16]\]. Tetsuya conducted a prospective study and found that IR is associated with coronary lipid-rich plaques in patients with abnormal glucose regulation \[[@B17]\]. Reports have also indicated that IL-6, a potential cardiometabolic biomarker expressing in human atherosclerotic lesions, has a close relationship with HOMA-IR \[[@B18]\]. Uli C argues that low adiponectin levels are frequently associated with insulin resistance, may have a closer link with coronary plaque vulnerability, which plays an important role in the pathogenesis of ACS \[[@B19]\]. Having enrolled 543 patients with diabetes and CHD and using the intravascular ultrasound (IVUS) technique to assess the progression of coronary atherosclerosis directly, the recent PERISCOPE study concluded that pioglitazone, a drug targeting IR, could significantly slow the progression of atherosclerosis, which is also supportive of our study \[[@B20]\].

Having confirmed the predictive value of IR on plaques progression, our study also looks into the issue of in-stent restenosis, an important complication of coronary arterial intervention nowadays \[[@B21]\]. Having observed similar prevalence of in-stent restenosis between the higher and lower IR groups, we set up the binary logistic regression model to evaluate the risk factors for in-stent restenosis by inputting the same variables as above. The results showed that unlike prevalence of HTN (OR = 0.241, *p* = 0.019) and age (OR = 1.084, *p* = 0.008), insulin resistance had no statistically significant effect on the development of in-stent restenosis (OR = 2.064, *p* = 0.218, table not shown). It has been well studied that the formation of in-stent restenosis depends on the proliferation of in-stent neointimal cells because of complex inflammatory responses in the short time interval, which is quite different from the process of plaque formation \[[@B21],[@B22]\]. This may serve to explain the results of our study. However, conflicting evidence does exist. A study in 2005 by Kazuaki stated that IR predicted in-stent restenosis rather than de-novo stenosis, which was mediated by atherosclerosis plaque progression \[[@B7]\]. Following the difference can be utilized to explain the differences in results between their study and ours according to the following facts: 1. the aim of the study by Kazuaki was to evaluate the IR's effect on restenosis after stenting, which resulted in the 110 recruited individuals were not just confined to subjects with CHD. Instead, the sample included patients who had extensive coronary artery dissection after PTCA, complete vessel closure, residual stenosis of 25% or more of the vessel diameter. 2. The follow-up interval in Kazuaki's study, which played an important role in the development of in-stent restenosis was 4-months. In our case, the interval was 1 year. 3. Instead of setting up a cutting value for HOMA-IR to determine the state of insulin resistance as we did, they set the HOMA-IR as a continuous variable. 4. The variables they used in the multivariable logistic regression model only included HbA1C, HOMA-IR and LDL-C, which in our case are risk factors such as age, sex, BMI, prevalence of hypertension and diabetes, HOMA-IR, HbA1c, hsCRP, LDL-C and urine MA/Cr. Based on these differences in the fundamental aspects of the studies, it seems inappropriate to compare their results with ours.

Our study also revealed that HbA1c also stands for an independent predictor of coronary plaque progression in unselected individuals. As a reliable marker of recent 2--3 months serum glucose level, HbA1c has already been used for diagnosing diabetes mellitus \[[@B23],[@B24]\]. In a recent meta-analysis covering 20 studies involving 13, 224 individuals suggested that HbA1c level was an independent risk factor for mortality in CHD patients without diabetes \[[@B25]\]. Hiroyasu also stated that HbA1c was an independent predictor of major adverse cardiac events after the implantation of DES \[[@B26]\]. Several other studies also support the role of HbA1c in future CVD event and mortalities \[[@B27]-[@B29]\].

Study limitations
-----------------

First, the number of subjects recruited in the study was limited and all individuals were enrolled from a single center at the Shanghai Ruijin hospital. In addition, the majority of patients originated from Shanghai, Jiangsu province and Zhejiang province, all confined to the southeast region of the Yangzi River in Mainland China. Moreover, due to the limited number of individuals in subgroups such as the IGT group (n = 57) and the IFG group (n = 39), our study did not perform the subgroup analysis and future studies may provide different results, as the pathogenesis of IGT is different from that of IFG concerning insulin resistance \[[@B30]\]. Finally, discordant views did exist in assessing insulin resistance by using the HOMA-IR method, including the lack of consensus on setting up a unified cutoff value for HOMA-IR to determine the state of IR \[[@B31]\]. We chose to set the upper quartile of HOMA-IR in the background population as its cutoff value \[[@B8],[@B10]\], which equaled 3.458 in our study. However, we also modeled HOMA-IR as a linear continuous variable and tested it from both perspectives in our regression model, and the results conformed to each other.

Conclusions
===========

Insulin resistance is an independent predictor for atherosclerosis plaque progression in patients with coronary heart disease in both the diabetic and non-diabetic population.
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